STOCK TITAN

United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 20, 2026, then sold an equal 9,500 shares in multiple open-market trades. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which permits the exercise of up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026. After this exercise, a family trust continues to hold 312,910 stock options, while Rothblatt also holds 40,513 common shares directly and 166 shares indirectly via her spouse.

Positive

  • None.

Negative

  • None.
Insider ROTHBLATT MARTINE A
Role Chairperson & CEO
Sold 9,500 shs ($5.05M)
Approx. gross sale proceeds $5.05M
Approx. exercise cost $1.29M
Approx. pre-tax spread $3.76M
Type Security Shares Price Value
Exercise Stock Option F1, F13 9,500 $0.00 $0.00
Exercise Common Stock F1, F2 9,500 $135.42 $1.29M
Sale Common Stock F1, F3, F2 1,831 $529.1887 $969K
Sale Common Stock F1, F4, F2 960 $529.8509 $509K
Sale Common Stock F1, F5, F2 1,660 $531.0771 $882K
Sale Common Stock F1, F6, F2 1,874 $532.0729 $997K
Sale Common Stock F1, F7, F2 1,686 $533.0268 $899K
Sale Common Stock F1, F8, F2 889 $534.1264 $475K
Sale Common Stock F1, F9, F2 520 $535.2044 $278K
Sale Common Stock F1 80 $536.41 $43K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock F10 -- -- --
holding Common Stock F11 -- -- --
holding Common Stock F12 -- -- --
Holdings After Transaction: Stock Option — 312,910 shares (Indirect, by Trust); Common Stock — 628,049 shares (Indirect, by Trust); Common Stock — 40,513 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (13)
  1. F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
  2. F10. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  3. F11. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  4. F12. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
  5. F13. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
  6. F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
  7. F3. This transaction was executed in multiple trades at prices ranging from $528.57 to $529.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F4. This transaction was executed in multiple trades at prices ranging from $529.57 to $530.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F5. This transaction was executed in multiple trades at prices ranging from $530.60 to $531.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. F6. This transaction was executed in multiple trades at prices ranging from $531.63 to $532.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  11. F7. This transaction was executed in multiple trades at prices ranging from $532.63 to $533.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  12. F8. This transaction was executed in multiple trades at prices ranging from $533.665 to $534.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  13. F9. This transaction was executed in multiple trades at prices ranging from $534.71 to $535.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Options exercised 9,500 shares Stock options converted into common stock on July 20, 2026
Exercise price $135.4200 per share Strike price of stock options exercised by family trust
Shares sold 9,500 shares Common stock sold in multiple open-market trades on July 20, 2026
Sale price example $529.1887 per share Weighted-average price for a 1,831-share sale tranche
Sale price high $536.4100 per share Price for an 80-share sale reported on July 20, 2026
Options remaining in trust 312,910 shares Stock options held indirectly after the reported exercise
10b5-1 plan capacity 1,734,410 stock options Maximum options eligible for exercise under the trading plan
Direct common shares 40,513 shares Common stock held directly as of July 20, 2026
Spouse-held shares 166 shares Common stock held indirectly through spouse
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did UNITED THERAPEUTICS (UTHR) report for Martine Rothblatt?

Martine Rothblatt, via family trusts, exercised 9,500 stock options at $135.42 per share on July 20, 2026, and sold an equal 9,500 common shares in multiple open-market trades on the same date under a Rule 10b5-1 trading plan.

At what prices were UNITED THERAPEUTICS (UTHR) shares sold in this Form 4?

The filing reports several tranches of sales, including 1,831 shares at $529.1887, 960 shares at $529.8509, and additional tranches up to 80 shares at $536.4100 per share, with some trades executed over stated intraday price ranges.

Was the UNITED THERAPEUTICS (UTHR) CEO trading under a Rule 10b5-1 plan?

Yes. A footnote states the option exercise and resulting share sales were under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until either 1,734,410 options are exercised or December 31, 2026, whichever comes first.

How many options are covered by the UNITED THERAPEUTICS (UTHR) trading plan?

The Rule 10b5-1 plan permits the exercise of up to 1,734,410 stock options, all expiring on March 15, 2027. The plan is scheduled to end at the earlier of those options being fully exercised or December 31, 2026.

What are Martine Rothblatt’s remaining UNITED THERAPEUTICS (UTHR) holdings after these trades?

After the reported option exercise, a family trust holds 312,910 stock options. Separately, Rothblatt holds 40,513 common shares directly and 166 shares indirectly through her spouse, plus additional unquantified indirect holdings through various family trusts referenced in the footnotes.

How are the UNITED THERAPEUTICS (UTHR) shares owned for these transactions?

The exercised options and sold shares are reported as held indirectly by family trusts where Rothblatt and/or her spouse share investment power and family members are beneficiaries, rather than as solely held directly in her personal name.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROTHBLATT MARTINE A

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairperson & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/20/2026M(1)9,500A$135.42333,943Iby Trust(2)
Common Stock07/20/2026S(1)1,831D$529.1887(3)332,112Iby Trust(2)
Common Stock07/20/2026S(1)960D$529.8509(4)331,152Iby Trust(2)
Common Stock07/20/2026S(1)1,660D$531.0771(5)329,492Iby Trust(2)
Common Stock07/20/2026S(1)1,874D$532.0729(6)327,618Iby Trust(2)
Common Stock07/20/2026S(1)1,686D$533.0268(7)325,932Iby Trust(2)
Common Stock07/20/2026S(1)889D$534.1264(8)325,043Iby Trust(2)
Common Stock07/20/2026S(1)520D$535.2044(9)324,523Iby Trust(2)
Common Stock07/20/2026S(1)80D$536.41324,443Iby Trust
Common Stock40,513D
Common Stock166Iby Spouse
Common Stock249,108Iby Trust(10)
Common Stock45,596Iby Trust(11)
Common Stock8,902Iby Trust(12)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$135.4207/20/2026M(1)9,50003/15/202303/15/2027Common Stock9,500$0.00312,910Iby Trust(13)
Explanation of Responses:
1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
3. This transaction was executed in multiple trades at prices ranging from $528.57 to $529.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $529.57 to $530.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $530.60 to $531.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $531.63 to $532.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $532.63 to $533.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $533.665 to $534.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $534.71 to $535.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
11. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
12. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
13. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)